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A B S T R A C T
Introduction. The Female Sexual Distress Scale-Revised (FSDS-R) was created and validated to assess distress
associated with impaired sexual function, but it is lengthy for use in clinical practice and research when assessing
sexual function is not a primary objective.
Aim. The study aims to evaluate whether a single item from the FSDS-R could be identiﬁed to use to screen midlife
women for bothersome diminution in sexual function based on three criteria: (i) highly correlated with total scores;
(ii) correlated with commonly assessed domains of female sexual functioning; and (iii) able to differentiate between
women reporting high and low sexual concerns during the prior month.
Methods. Data from 93 midlife women were collected by the Menopause Strategies Finding Lasting Answers to
Symptoms and Health (MsFLASH) research network.
Main Outcome Measures. Women completed the FSDS-R, Female Sexual Function Index (FSFI), and Menopausal
Quality of Life Scale (MENQOL). Those who reported a change in the past month on the MENQOL sexual were
categorized into a high sexual concerns group, while all others were categorized into a low sexual concerns group.
Results. Women were an average of 54.6 years old (SD 3.1) and mostly Caucasian (77.4%), college educated
(60.2%), married/living as married (64.5%), and postmenopausal (79.6%). The FSDS-R item number 1 “Distressed
about sex life” was: (i) highly correlated with FSDS-R total scores (r = 0.90); (ii) moderately correlated with FSFI
total scores (r = −0.38) and FSFI desire (r = −0.37) and satisfaction domains (r = −0.40); and (iii) showed one of the
largest mean differences between high and low sexual concerns groups (P < 0.001). Other FSDS-R items met one or
two, but not all three of the prespeciﬁed criteria (i, ii, iii).
Conclusions. A single FSDS-R item may be a useful screening tool to quickly identify midlife women with sexually
related distress when it is not feasible to administer the entire scale, though further validation is warranted.
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Introduction
Sexual function is an important aspect of qualityof life for most women, but is known to be of
particular importance for midlife women as hor-
monal changes may result in untoward skin, vas-
cular and neuronal changes [1,2]. Practitioners
rarely ask their patients about sexual function at
midlife, and women rarely volunteer that they are
distressed or affected by diminishing sexual func-
tion [3]. A single item question that could screen
women for bothersome diminution in sexual func-
tion could provide direction for more in-depth
clinical conversations and greatly improve health
care for women receiving primary care by family
practitioners, internists, and gynecologists. It may
also be beneﬁcial for use in research studies where
assessing sexual function is not a primary objective.
Current deﬁnitions of female sexual dysfunc-
tion from the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-V) include
problems with desire, arousal, orgasm, or pain that
cause marked distress or interpersonal difﬁculty
[4]. Current diagnostic criteria require an assess-
ment of both symptoms and symptom-associated
distress. One of the most commonly used instru-
ments used to diagnose sexual dysfunction in clini-
cal gynecologic and urogynecologic practices and
in research settings is the Female Sexual Function
Index (FSFI) [5]; however, it does not assess dis-
tress and it is somewhat lengthy, with a total of 19
items. Many women have distress around dimin-
ishing sexual function, but do not screen positive
for one of the DSM-V sexual function disorders.
Starting conversations around sexual function with
a single screening question that identiﬁes women
“bothered” by their sexual function would be of
value.
The Female Sexual Distress Scale-Revised
(FSDS-R) was created and validated to assess sexu-
ally related distress—that is, distress associated
with inadequate or impaired sexual function. An
evaluation of the original scale (FSDS) among 500
women showed a ﬁnal 12-item version to be a
psychometrically sound, unidimensional measure
[6]. Subsequently, a revised 13-item scale
(FSDS-R) was devised that also showed strong
psychometric properties, including the ability to
assess sexually related distress in women with
hypoactive sexual desire disorder or serve as a
screening tool to identify women with high and
low sexual function [7]. The FSDS and/or
FSDS-R have been widely adopted and are avail-
able in 10 different languages, with translated
scales also demonstrating strong internal consis-
tency, reliability, and validity [7–9]. However, its
multiple items can be lengthy for use in research
where assessing sexual function is not the primary
objective of the clinical trial. In these studies,
sexual function typically is only one of multiple
end points assessed, and subjects are completing a
large number of questionnaires. In addition to its
utility in research, a validated single item to assess
sexually related distress could be very helpful in
clinical practice to standardize quick identiﬁcation
of women who would beneﬁt from a more com-
prehensive assessment and/or referral to practitio-
ners with expertise in assessing and treating sexual
dysfunction.
Aims
The purpose of this analysis was to evaluate
whether a single item from the FSDS-R could be
identiﬁed to use to screen women for bothersome
diminution in sexual function based on three cri-
teria: (i) highly correlated with total scores; (ii)
correlated with commonly assessed domains of
female sexual functioning; and (iii) able to differ-
entiate between women who reported high and
low sexual concerns on a validated questionnaire
during the prior month.
Methods
Design
This was a cross-sectional analysis of baseline data
collected from the second trial conducted by the
Menopause Strategies: Finding Lasting Answers
to Symptoms and Health (MsFLASH) research
network. Study methods and ﬁndings are pub-
lished elsewhere [10–14]. Brieﬂy, the trial com-
pared yoga, exercise, and omega-3 fatty acid
supplements to placebo for the treatment of
menopausal hot ﬂashes in symptomatic women.
Although the study was conducted at three sites,
only women at the Seattle site completed the
FSDS-R, as investigators at the other sites
believed the questionnaire was too lengthy for
subjects already completing a large battery of
questionnaires related to the study’s principal
objectives, including assessments of vasomotor
symptoms, sleep, and mood. At the Seattle site,
recruitment occurred between November 9, 2010
and February 8, 2012, and data collection occurred
between February 16, 2011 and May 1, 2012.
Setting and Participants
Participants were recruited primarily by mass
mailings. Eligible participants were 40–62 years
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old, postmenopausal (≥12 months since the last
menstrual period or bilateral oophorectomy) or in
the late menopausal transition (amenorrhea ≥60
days in the past year), in good general health
according to medical history, and reporting ≥14
hot ﬂashes per week and rated as severe or both-
ersome on ≥4 days or nights per week. Women
were excluded for use of any hot ﬂash treatments,
current severe medical illness or major depressive
episode, conditions that interfered with ability to
tolerate the interventions, such as physical limita-
tions, high ﬁsh consumption, or serious medical
illnesses.
Procedures
Following a telephone screening that included
verbal consent, women maintained hot ﬂash
diaries for 2 weeks. Those who continued to be
eligible provided written informed consent and
took part in two baseline assessments 1 week apart.
Questionnaires used in this analysis were com-
pleted at the ﬁrst or second baseline visit by
the Seattle participants. Study staff were available
to address questions or concerns, but did not
otherwise direct participants in ﬁlling out the
questionnaires.
Main Outcome Measures
Demographic data collected on a form included
menstrual history to determine menopausal status,
age, race/ethnicity, education, and marital status.
Height and weight were measured by a clinic staff
to determine body mass index. Women were also
asked to rate their current health status from 1
(poor) to 5 (excellent).
For the 13-item FSDS-R, women rated each
item in terms of frequency from 0 (never) to 4
(always). Items were summed to create a total
score ranging from 0 to 52, with higher scores
indicating more sexually related distress.
Cronbach’s alpha for the scale in our participants
was 0.95.
Two other questionnaires were used in the
analysis. The FSFI is a 19-item assessment of
sexual function over the past 4 weeks [5]. The scale
includes six domains (desire, subjective arousal,
lubrication, orgasm, satisfaction, and pain). Indi-
vidual domain scores are as follow: 1.2–6 for
desire; 0–6 for arousal, lubrication, orgasm, and
pain; and 0.8–6 for satisfaction. Total scores range
from 2 to 36, with lower scores indicating higher
symptom burden. Cronbach’s alpha was 0.91. In
addition, the three items that comprise the sexual
domain from the 30-item Menopausal Quality of
Life Scale (MENQOL) were used in this analysis
[15]. Women were categorized as having high
sexual concerns if they responded yes to all three
MENQOL sexual domain items: (i) experiencing
diminished sexual desire; (ii) avoidance of inti-
macy; and (iii) vaginal dryness. All other respon-
dents were categorized as having low sexual
concerns.
Data Analysis
Sample demographics were summarized using
descriptive statistics (n = 93). Frequencies for indi-
vidual FSDS-R items were calculated. Pearson
correlations were calculated for: FSDS-R item to
FSDS-R total, FSDS-R item to FSFI total, and
FSDS-R item to FSFI domain scores. Then based
on MENQOL scores, women were divided into
high (n = 20) and low (n = 72) sexual concerns
groups. FSDS-R item means were compared
between groups via two-sample t-tests.
A total sample size of 93 participants provided
83% power to detect a correlation coefﬁcient as
small as 0.3, based on a two-sided 0.05 signiﬁcance
level. In addition, sexual concerns subgroups of 20
and 72 provided 80% power to detect an effect size
of 0.72 standard deviation (SD) unit difference
between groups, based on a two-sample t-test with
two-sided 0.05 signiﬁcance level. An effect size is
deﬁned as the difference between the groups’
means, divided by their common SD. Observed
effect sizes, calculated as Glass’ delta due to
inequality in variances between groups, ranged
from 0.5 to 1.6 SD.
Results
The 93 participants at the Seattle site completed
the FSDS-R, the FSFI, and both MENQOL
items. There were 20.4% who were missing one or
more items on at least one of the three question-
naires: FSDS-R (2.2%), FSFI (3.2%), and
MENQOL (19.4%). All available data were
included in each individual analysis. While FSFI
total and satisfaction scores had a 19.4% rate of
missing data, only 3.3% or fewer participants were
missing data for all other outcome variables.
Demographic characteristics were as follows.
Participants’ mean age was 54.6 years old (SD =
3.1). Women were Caucasian (77.4%), African
American (9.7%), or other ethnicities (12.9%).
Most held a college degree (60.2%) and were
married or living as married (64.5%). Women
were postmenopausal (79.6%) or perimenopausal
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(20.4%). Most had a body mass index below 30
(67.3%), and most self-reported their health as
very good or excellent (69.9%).
Table 1 shows the distribution of responses on
the FSDS-R. Women most frequently endorsed 0
or 1, indicating no or little sexually related distress
for the majority of items. The median score for all
participants was 10.0 (interquartile range = 2 to
17). Women were least likely to endorse being
“angry about sex life” or feeling “inferior because
of sex problems.”
Table 2 depicts correlations between FSDS-R
items and FSDS-R total, FSFI total, and FSFI
domains. Item 1, distress about sex life, was the
FSDS-R item most highly correlated with
FSDS-R total scores. Distress about sex life was
tied with item 2, “unhappy about sexual relation-
ship,” as the FSDS-R items most highly correlated
with FSFI total scores. FSDS-R items were gen-
erally not as highly correlated with FSFI domain
scores as with FSFI total scores. FSDS-R items
were modestly correlated with FSFI domains of
desire and satisfaction, and poorly correlated with
other FSFI domains. However, distress about sex
life was one of the three items most highly corre-
lated with FSFI desire and satisfaction domain
scores.
Shown in Table 3 are differences in FSDS-R
items between high and low sexual concerns
groups, classiﬁed based on the MENQOL sexual
domain scores. Of note is that all but one FSDS-R
item was signiﬁcantly higher in the high sexual
concerns group compared with the low sexual con-
cerns group. The largest mean differences were for
Table 1 Distribution of responses to the Female Sexual Distress Scale-Revised (FSDS-R) items (n = 93)
Never Rarely Occasionally Frequently Always
0 1 2 3 4
n % n % n % n % n %
1. Distressed about sex life 28 30 33 36 20 22 7 8 5 5
2. Unhappy about sexual relationship 28 30 28 30 22 24 10 11 4 4
3. Guilty about sexual difficulties 43 46 26 28 10 11 11 12 3 3
4. Frustrated by sexual problems 44 47 23 25 15 16 7 8 4 4
5. Stressed about sex 46 50 24 26 12 13 9 10 2 2
6. Inferior because of sexual problems 62 67 17 18 8 9 4 4 1 1
7. Worried about sex 47 51 22 24 16 17 7 8 1 1
8. Sexually inadequate 50 54 18 19 16 17 6 7 3 3
9. Regrets about sexuality 56 60 15 16 14 15 6 7 2 2
10. Embarrassed about sexual problems 57 61 20 22 10 11 3 3 3 3
11. Dissatisfied with sex life 31 33 19 20 27 29 9 10 7 8
12. Angry about sex life 66 71 16 17 8 9 1 1 2 2
13. Bothered by low sexual desire 36 39 15 16 22 24 13 14 7 8
Table 2 Pearson correlation coefficients between FSDS-R items and FSDS-R total scores, FSFI total scores, and FSFI
domain scores
FSDS-R
Total FSFI Total
FSFI Domains
Desire Arousal Lubrication Orgasm Satisfaction Pain
Distressed about your sex life 0.90*** −0.38*** −0.37*** −0.15 −0.09 −0.06 −0.40*** −0.06
Unhappy about your sexual relationship 0.76*** −0.38*** −0.23* −0.15 −0.08 −0.03 −0.52*** −0.15
Guilty about sexual difficulties 0.79*** −0.34*** −0.38*** −0.21 −0.05 −0.15 −0.29* −0.05
Frustrated by your sexual problems 0.86*** −0.33** −0.35*** −0.15 −0.09 −0.11 −0.31** −0.09
Stressed about sex 0.81*** −0.22** −0.21* −0.07 −0.01 −0.01 −0.24* −0.03
Inferior because of sexual problems 0.81*** −0.23 −0.28** −0.17 −0.06 −0.11 −0.25* −0.07
Worried about sex 0.81*** −0.28* −0.34*** −0.22* −0.08 −0.14 −0.36** −0.11
Sexually inadequate 0.82*** −0.30* −0.34** −0.18 −0.12 −0.12 −0.29* −0.12
Regrets about your sexuality 0.69*** −0.12 −0.18 −0.01 −0.04 0.03 −0.09 −0.01
Embarrassed about sexual problems 0.79*** −0.34** −0.36*** −0.24* −0.14 −0.18 −0.29* −0.16
Dissatisfied with your sex life 0.74*** −0.32** −0.23* −0.09 −0.02 −0.01 −0.52*** −0.09
Angry about your sex life 0.72*** −0.30** −0.17 −0.17 −0.10 −0.13 −0.36** −0.10
Bothered by low sexual desire 0.71*** −0.30** −0.40*** −0.08 −0.05 −0.03 −0.29* 0.07
*P < 0.05, **P < 0.01, ***P < 0.001.
FSDS-R = Female Sexual Distress Scale-Revised, high scores = greater frequency of problems, n = 93.
FSFI = Female Sexual Function Index, lower scores = higher symptom burden, n = 93.
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FSDS-R items of distress about sex life, sexual
inadequacy, frustrated about sex life, and bothered
by low desire.
Conclusions
This analysis was undertaken in an effort to iden-
tify a potential single-item screening question to
quickly identify women who may be experiencing
sexually related distress, in hopes of increasing the
likelihood that this important end point is assessed
in both clinical practice and research. In research,
a simple assessment could be very valuable when
sexual function is not the primary focus of a clinic
visit or a study. For example, an assessment of
sexually related distress is currently not included in
large randomized controlled trials of new drugs for
hypertension, diabetes, or cancer treatments. A
validated single item could easily be added to the
large battery of questionnaires completed in these
trials without increasing subject burden. If a sig-
niﬁcant effect on sexual distress was identiﬁed,
more extensive and detailed investigation then
would be required to determine what aspects of
sexual function were affected. In clinical practice,
clinicians rarely ask women about sexual problems,
despite a high prevalence of distressing sexual
problems, especially in midlife women [3,16]. The
availability of a validated single item to standardize
quick identiﬁcation of sexually related distress
would be very helpful in general clinical practice to
identify women who would beneﬁt from further
evaluation or referral to practitioners with exper-
tise in sexual dysfunction.
Results demonstrate that a single FSDS-R item
pertaining to distress about sex life (item 1) per-
formed well based on prespeciﬁed criteria. This
item was most highly correlated with FSDS-R
total scores, among the most highly correlated
items with FSFI total and domain scores, and was
among the top items showing the greatest mean
difference between high and low sexual concerns
groups. It is not surprising that the FSDS-R dis-
tress item 1 emerged as a central item, given the
importance of the construct in the deﬁnition of
sexual function [4,6]. Other FSDS-R items met
one or two of our prespeciﬁed criteria, but not all
three criteria.
To our knowledge, prior studies have not evalu-
ated a single-item screening question for sexual
function distress. Research has focused on evalu-
ating the FSDS-R single item related to sexual
desire bother (item 13) rather than distress about
sex life (item 1) among women with DSM-V sexual
dysfunction disorders [17]. Using data from 738
women from the United States, Canada, and
Europe, FSDS-R total scores and responses to
FSDS-R item 13 were found to differentiate
between groups with and without hypoactive
sexual desire, but not between groups with other
different types of sexual dysfunction. Similar
analyses for distress about sex life (item 1) were not
reported. In our study, item 13 did not perform as
well as item 1, probably because we wished to
identify an item that assessed global sexual func-
tion rather than disorders of desire. While item 13
did differentiate between high and low sexual con-
cerns groups, it was less highly correlated with
FSDS-R total, FSFI total, and FSFI domain scores
in comparison with item 1. Further analyses in
larger populations would be needed to determine
Table 3 Mean with 95% confidence interval of FSDS-R items between MENQOL high and low sexual concerns groups*
High concerns
(n = 20)
Low concerns
(n = 72)
Effect
size† P ‡
1. Distressed about your sex life 2.1 (1.5, 2.7) 1.0 (0.8, 1.2) 1.1 <0.001
2. Unhappy about your sexual relationship 2.1 (1.5, 2.7) 1.1 (0.8, 1.3) 1.0 <0.001
3. Guilty about sexual difficulties 1.8 (1.2, 2.4) 0.8 (0.5, 1.0) 1.0 <0.001
4. Frustrated by your sexual problems 2.0 (1.4, 2.5) 0.7 (0.5, 0.9) 1.3 <0.001
5. Stressed about sex 1.6 (0.9, 2.3) 0.7 (0.5, 0.9) 1.0 0.012
6. Inferior because of sexual problems 1.1 (0.4, 1.7) 0.4 (0.2, 0.6) 0.9 0.044
7. Worried about sex 1.4 (0.8, 2.0) 0.7 (0.5, 0.9) 0.8 0.036
8. Sexually inadequate 1.8 (1.1, 2.4) 0.6 (0.4, 0.8) 1.3 <0.001
9. Regrets about your sexuality 1.3 (0.7, 1.9) 0.6 (0.4, 0.8) 0.7 0.009
10. Embarrassed about sexual problems 1.4 (0.7, 2.1) 0.5 (0.3, 0.6) 1.3 0.013
11. Dissatisfied with your sex life 2.1 (1.6, 2.6) 1.2 (0.9, 1.5) 0.8 0.004
12. Angry about your sex life 0.8 (0.4, 1.2) 0.4 (0.2, 0.6) 0.5 0.053
13. Bothered by low sexual desire 2.8 (2.3, 3.2) 1.0 (0.7, 1.3) 1.6 <0.001
*High sexual concerns defined as “Yes” to experiencing a change in sexual desire, avoiding intimacy, and vaginal dryness in past month on Menopausal Quality
of Life Scale (MENQOL).
†Effect size (Glass’ delta).
‡P values from a two-sided two-sample t-test.
FSDS-R = Female Sexual Distress Scale-Revised.
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whether FSDS-R item 1 differentiates women
with different types of sexual dysfunction and
whether the FSDS-R item 1 would be useful in
clinical settings, opening up patient–provider dis-
cussions that otherwise rarely occur.
Correlations within the FSDS-R and between
the FSDS-R and FSFI total and domain scores are
somewhat difﬁcult to interpret due to the lack of
comparable published data. Several prior psycho-
metric analyses did not report FSDS-R item to
total correlations [5–8,17] or FSDS-R to FSFI cor-
relations [5–8,17]. However, correlations were
reported for the Farsi version of the FSDS-R
among 1,966 Iranian women, most of whom did
not report female sexual dysfunction (67%). Farsi
FSDS-R item to total correlations ranged from
0.67 to 0.82 (P < .001) [18], which are lower than
in our study using the English language version. In
addition, correlations between the Farsi FSDS-R
total and FSFI dimensions were −0.16 to 0.40
(P < .001) [18], which are comparable with our
results.
It is possible that the strength of correlations we
observed may have varied based on a woman’s
sexual activity. For example, correlations between
the Sexual Health Outcomes inWomenQuestion-
naire (SHOW-Q) and health-related quality of
life, body image, and symptom scales varied based
on whether or not a woman was sexually active
[19].
Limitations include the following. We did not
collect data on sexual frequency, partner gender, or
history of physical or sexual abuse. The number of
study subjects was relatively small and limited to a
single geographic area. Only women at a single
MsFLASH site completed the FSDS-R due to
concerns from principal investigators at all other
research sites about subject burden. In addition,
the sample was predominantly Caucasian, college
educated, and married/living as married. The
sample was (i) limited to menopausal women with
hot ﬂashes and other symptoms; and (ii) not spe-
ciﬁcally selected based on sexual dysfunction, so
we relied on MENQOL items to differentiate
high and low sexual concerns groups based on
desire and symptoms, important aspects of
DSM-V criteria. The MENQOL is a validated,
widely used measure of menopausal symptoms,
and the sexual function domain is a validated
subscale. The FSFI is a more comprehensive
measure of sexual function, but it was not used to
determine high and low sexual concerns groups in
this study, as then it could not have been used in
the assessment of construct validity.
In summary, the single FSDS-R item “distress
about your sex life” (item 1) may serve as a useful
single item in screening women for sexually
related distress when time or subject burden is an
issue. Replicating our analyses in larger and more
diverse populations of all ages and with attention
to evaluating sensitivity to change or intervention
effects occurring over time is warranted.
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